Phaseline

Companies › Beijing Youcare Kechuang Pharmaceutical Technology

Beijing Youcare Kechuang Pharmaceutical Technology: clinical trials, targets and expected readouts

3 active drug programs in 3 registered trials: 3 Phase 1; Cardiovascular, Oncology, Infectious disease; next expected readout Nov 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
YKYY033 Injection–Phase 1Venous Thromboembolism (VTE)Nov 2027
YKYY031 for injection–Phase 1Malignant NeoplasmsDec 2027
YKYY025–Phase 1Respiratory Syncytial Virus (RSV)Jul 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07786779YKYY033 InjectionPhase 1Venous Thromboembolism (VTE)CardiovascularNov 2027
NCT07631793YKYY031 for injectionPhase 1Malignant NeoplasmsOncologyDec 2027
NCT07694557YKYY025Phase 1Respiratory Syncytial Virus (RSV)Infectious diseaseJul 2028

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.